Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06398639 · ClinicalTrials.gov registry record · NA
Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer
A NA study of Prostate Cancer and Polygenic Risk Score, sponsored by Adam S. Kibel, MD.
- Recruiting
- Registry status
- NA
- Development phase
- 1,500
- Enrollment target
- 5
- Study locations
NCT06398639: Recruiting NA study of Prostate Cancer and Polygenic Risk Score, sponsored by Adam S. Kibel, MD.
NCT06398639 is a NA study of Prostate Cancer and Polygenic Risk Score that is actively recruiting participants, run by Adam S. Kibel, MD. The registered enrollment target is 1,500 participants, above the 606-participant average among 735 other Prostate Cancer trials with a reported enrollment target (148% higher). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06398639, a NA study of Prostate Cancer and Polygenic Risk Score, is actively recruiting participants, sponsored by Adam S. Kibel, MD.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,500 participants
- Enrollment target
- 5
- Study locations
Study Summary
The goal of this clinical trial is to evaluate a screening method to detect clinically relevant prostate cancer. This clinical trial is using genetic data to determine a man's risk of cancer, together with multiparametric magnetic resonance imaging (mpMRI) to identify men with higher grade cancer. The main questions it aims to answer are: * If genetic data related to prostate cancer used with MRI can identify higher-grade, potentially fatal prostate cancer * What age a MRI is useful clinically for prostate cancer screening * If deep learning methods used with MRI when the genetic risk of the man is known can more accurately predict significant cancers Participants will: * Get a prostate specific antigen (PSA) blood test * Get an mpMRI * Get the results of their genetic data to determine if they are considered high-, intermediate-, or low-risk for prostate cancer based on the trials genetic testing * Follow-up for this trial based on the participants risk and findings from the PSA test and mpMRI
Primary Outcome
The ratio between men with high PRS and intermediate PRS in each of the three age groups (40-54, 55-64, 65-69) regardless of their ethnicity.
Conditions Studied
Interventions
- OTHER Polygenic Risk Score (PRS)
Study Locations (5)
Maryland
- National Cancer Institute - Bethesda
- Walter Reed National Military Medical Center - Bethesda
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
District of Columbia
- Howard University Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2024-05-07 |
| Est. Completion | 2030-04-30 |
| Phase | NA |
What NCT06398639 shows while recruiting
NCT06398639 is an interventional study that assigns participants to a tested intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, above the 606-participant average among 735 other Prostate Cancer trials with a reported enrollment target (148% higher).
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Polygenic Risk Score (PRS) is the first listed.
NCT06398639 lists 5 locations in 3 states (Maryland, Massachusetts, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT06398639 about?
NCT06398639 is a clinical study titled "Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer". The goal of this clinical trial is to evaluate a screening method to detect clinically relevant prostate cancer. This clinical trial is using genetic data to determine a man's risk of cancer, together with multiparametric magnetic resonance imaging (mpMRI) to identify men with higher grade cancer. ...
What is the current status of trial NCT06398639?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,500 participants. The study started on 2024-05-07. Estimated completion is 2030-04-30.
What conditions does trial NCT06398639 study?
This clinical trial studies the following conditions: Prostate Cancer, Polygenic Risk Score.
What interventions are being tested in trial NCT06398639?
The interventions under investigation include: Polygenic Risk Score (PRS) (OTHER).
Who is sponsoring clinical trial NCT06398639?
This trial is sponsored by Adam S. Kibel, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06398639 being conducted?
This trial has 5 study locations across District of Columbia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06398639's enrollment target sits among peer trials
1,500 36th of 735 higher than 699 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI